Leaders representing the French and Netherlands governments have urged for funding to develop new treatment and prevention tools against drug-resistant tuberculosis (TB) at a meeting held in Brussels.
Infectex announced that it had found positive results from its latest Phase 2b-3 clinical trial of its drug for multidrug-resistant pulmonary tuberculosis.
A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB